Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Itraconazole on Lorlatinib PK in Healthy Volunteers
NCT02838264Phase 1Completed
- Sponsor
- Pfizer
- Start
- Aug 2016
- Primary completion
- Mar 2017
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of lorlatinib in non-small cell lung cancer (NSCLC) (4 cohorts), sponsored by Pfizer. Primary endpoints: Area Under the Curve to Infinity and Maximum Plasma Concentration. Started Aug 2016; status: completed.
02
Drugs
lorlatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02838264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02838264.